tiprankstipranks
Trending News
More News >
GRI Bio (GRI)
NASDAQ:GRI
US Market
Advertisement

GRI Bio (GRI) AI Stock Analysis

Compare
194 Followers

Top Page

GRI

GRI Bio

(NASDAQ:GRI)

Rating:45Neutral
Price Target:
GRI Bio's stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
Positive Factors
Clinical Trials
The completion of enrollment in the Phase 2a study for GRI-0621 in idiopathic pulmonary fibrosis patients marks a positive milestone for GRI Bio.
Financial Stability
GRI Bio's solid financial foundation is supported by sufficient cash reserves into 2026, bolstered by $5 million raised in the current quarter.
Safety Profile
GRI-0621 is well-tolerated, with no meaningful changes in HDL, LDL, or triglycerides, showcasing a favorable safety profile and de-risking future data readouts.
Negative Factors
Clinical Risks
Despite the high potential rewards, there are substantial risks associated with clinical trials, which could impact GRI Bio's stock.
Market Challenges
The evolving NKT space presents challenges, as it requires careful and deliberate trial design to unlock both clinical and commercial potential.

GRI Bio (GRI) vs. SPDR S&P 500 ETF (SPY)

GRI Bio Business Overview & Revenue Model

Company DescriptionGRI Bio (GRI) is a biotechnology company focused on developing innovative therapies to address unmet medical needs in the field of immunology. The company's core products and services revolve around its proprietary platform technology, which aims to modulate immune system responses to treat chronic inflammatory and fibrotic diseases. GRI Bio operates at the intersection of biotechnology and pharmaceuticals, striving to bring novel therapeutic solutions to market.
How the Company Makes MoneyGRI Bio generates revenue through the development and commercialization of its proprietary therapies. The primary revenue streams include licensing agreements with pharmaceutical companies and potential milestone payments and royalties from successful drug candidates developed using their platform technology. Additionally, GRI Bio may engage in strategic partnerships and collaborations with other biotech firms to co-develop and market new therapies. The company's earnings are significantly influenced by its ability to advance drug candidates through clinical trials and secure regulatory approvals, as well as the establishment of lucrative partnerships with larger pharmaceutical entities.

GRI Bio Financial Statement Overview

Summary
GRI Bio shows progress in revenue and equity but faces profitability and cash flow challenges. The high operational costs and cash burn pose risks, despite a strong equity position.
Income Statement
45
Neutral
GRI Bio's income statement shows some improvement in revenue from the previous year, with a TTM (Trailing-Twelve-Months) total revenue of $4.91 million, up from $0 in 2022. However, the company continues to face significant challenges in profitability, as indicated by negative net income and EBIT margins. The EBIT margin for the TTM is -103.5%, and the net profit margin is -167%, highlighting ongoing operational inefficiencies and high costs relative to revenue.
Balance Sheet
52
Neutral
The balance sheet reflects a stronger equity position, with stockholders' equity of $56.33 million as of the latest period, a recovery from previous negative equity figures. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage, which could be a positive factor in reducing financial risk. The equity ratio stands at 98.14%, showcasing a strong equity base relative to total assets, albeit with limited asset growth.
Cash Flow
40
Negative
GRI Bio's cash flow statement shows a negative operating cash flow and free cash flow in the TTM, with free cash flow at -$8.61 million. The operating cash flow to net income ratio is 1.05, suggesting the company is burning cash at a rate close to its net losses. Free cash flow growth remains negative, indicating ongoing challenges in generating cash from operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00100.00K
Gross Profit-1.00K0.000.000.000.000.00
EBITDA-11.28M-8.23M-10.90M-2.51M-963.00K-4.71M
Net Income-11.25M-8.21M-13.04M-3.22M-1.56M-4.82M
Balance Sheet
Total Assets4.04M5.74M2.96M383.00K8.34M955.00K
Cash, Cash Equivalents and Short-Term Investments3.28M5.03M1.81M9.00K7.51M109.00K
Total Debt108.00K119.00K14.00K673.00K169.00K336.00K
Total Liabilities2.84M1.71M2.70M2.01M2.52M2.41M
Stockholders Equity1.21M4.03M259.00K-1.63M5.82M-1.45M
Cash Flow
Free Cash Flow-10.35M-8.61M-9.15M-1.09M-8.31M-3.71M
Operating Cash Flow-10.35M-8.61M-9.14M-1.08M-8.31M-3.71M
Investing Cash Flow0.000.00-8.00K-3.00K-3.84M-2.00K
Financing Cash Flow11.82M11.83M10.95M1.01M15.75M-4.00K

GRI Bio Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.96
Price Trends
50DMA
1.53
Positive
100DMA
2.40
Negative
200DMA
7.07
Negative
Market Momentum
MACD
0.15
Negative
RSI
57.76
Neutral
STOCH
69.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Neutral. The current price of 1.96 is above the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.53, and below the 200-day MA of 7.07, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 57.76 is Neutral, neither overbought nor oversold. The STOCH value of 69.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRI.

GRI Bio Risk Analysis

GRI Bio disclosed 58 risk factors in its most recent earnings report. GRI Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

GRI Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
C$205.89M-3.31-23.14%2.77%20.79%-0.36%
45
Neutral
$5.34M-468.00%98.55%
38
Underperform
$136.26K-174.06%-10.75%82.25%
33
Underperform
$1.94M-237.69%-97.16%
30
Underperform
$1.58M-300.16%79.57%
29
Underperform
$9.33M-192.72%56.26%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GRI
GRI Bio
1.96
-11.05
-84.93%
SCPX
Scorpius Holdings
0.01
-6.22
-99.84%
SLRX
Salarius Pharmaceuticals
1.00
-1.56
-60.94%
PCSA
Processa Pharmaceuticals
0.22
-1.88
-89.52%
ONCO
Onconetix
3.62
-523.38
-99.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025